Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury: A Randomized Clinical Trial

IMPORTANCE: SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed. OBJECTIVE: To test the efficacy of losartan to...

Descripción completa

Detalles Bibliográficos
Autores principales: Puskarich, Michael A., Ingraham, Nicholas E., Merck, Lisa H., Driver, Brian E., Wacker, David A., Black, Lauren Page, Jones, Alan E., Fletcher, Courtney V., South, Andrew M., Murray, Thomas A., Lewandowski, Christopher, Farhat, Joseph, Benoit, Justin L., Biros, Michelle H., Cherabuddi, Kartik, Chipman, Jeffrey G., Schacker, Timothy W., Guirgis, Faheem W., Voelker, Helen T., Koopmeiners, Joseph S., Tignanelli, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928006/
https://www.ncbi.nlm.nih.gov/pubmed/35294537
http://dx.doi.org/10.1001/jamanetworkopen.2022.2735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928006/
https://www.ncbi.nlm.nih.gov/pubmed/35294537
http://dx.doi.org/10.1001/jamanetworkopen.2022.2735

Ejemplares similares